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Abstract
Background: The analysis of microbiome in respiratory samples is a topic of great interest in chronic respiratory
diseases. The method used to prepare sputum samples for microbiome analysis is very heterogeneous. The
selection of the most suitable methodology for DNA extraction is fundamental to have the most representative
data. The objective of this study was to compare different conditions for DNA extraction from sputum in adult
patients with bronchiectasis.
Methods: Five sputum samples from bronchiectasis patients were collected at the Policlinico Hospital in Milan,
Italy. Eighteen conditions for DNA extraction were compared, including two enzyme-based (Roche and Zymo)
and one beads-based (Mobio) technique. These techniques were tested with/without Dithiothreitol (DTT) and
with/without lysostaphin (0.18 and 0.36 mg/mL) step. DNA was quantified, tested using Real-time PCR for 16S rDNA
and S. aureus and, then, microbiome was evaluated.
Results: Although 16S rDNA was similarly detected across all the different techniques, Roche kit gave the highest
DNA yield. The lowest Ct values for Real-time PCR for S. aureus was identified when lysostaphin was added.
Considering genera from microbiome, alpha diversity indices did not show any significant differences between
techniques, while relative abundances were more similar in presence of DTT.
Conclusions: None of the conditions emerged to be superior to the others even if enzyme-based kits seem to be
needed in order to have a higher extraction yield.
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Background
Respiratory microbiome is a topic of great interest
nowadays in translational research for chronic respira-
tory diseases [1]. Most of the published experiences on
respiratory microbiome enrolled chronic obstructive
pulmonary disease (COPD) and bronchiectasis patients,
including those with cystic fibrosis, and sputum has
been the sample most commonly used by investigators
[2–5]. Sputum collection represents an easy and
non-invasive strategy for studies on respiratory micro-
biome. So far, sequencing of microbial communities from
airway samples through meta-omic approaches, mainly
based on high-throughput DNA sequencing techniques,
has been confined to scientific research. Although the use
of respiratory microbiome analysis has not been
implemented in clinical practice yet, a possible role of this
technique in stratifying patients for disease severity and
predicting clinical outcomes could be considered [6].
The choice of an appropriate methodology for evaluating
the microbiome in sputum samples is crucial to identify
the largest biodiversity as possible and to obtain reliable
and comparable results. It is a precocious phase for the
development of DNA extraction methods from sputum
and there is an extreme heterogeneity of DNA extraction
technique in literature. However, in this respect, several
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challenges could be identified. First, sputum is a substrate
with a complex and very difficult-to-manage matrix. The
use of different techniques for DNA extraction from spu-
tum might be limited by its nature. In order to facilitate its
treatment, a solubilizing agent, such as dithiothreitol
(DTT), is usually used [7]. Second, epidemiological data on
chronic respiratory infections in bronchiectasis and cystic
fibrosis revealed the presence of hard-to-lyse bacteria, such
as Staphylococcus aureus, leading to the possible need of
an individualized strategy to enhance bacterial lysis, such
as the use of enzymes able to specifically target
Gram-positive bacteria [8]. Pre-treatments with lysostaphin
and lysozyme, which are able to target cell wall peptidogly-
can and pentaglycine bridges respectively, have been re-
ported in literature for microbiome analysis [9, 10]. Third,
sputum complex and viscous matrix might represent a
limitation for broadly used DNA extraction techniques.
Among them, chemical coupled with enzymatic lysis is
extensively used to treat biological fluids and tissues, while
mechanical disruption is usually suggested for soil or feces.
Fourth, the bioinformatic approach is not standardized and
several pipelines are constantly emerging that can be ap-
plied to the analysis of microbiome data generated using
next-generation sequencing (NGS) techniques. Finally,
largely different methodologies, including steps ranging
from wet laboratory practices to in silico data analysis, have
been published in literature, limiting the comparability of
results across different experiences [2, 5, 11]. It is, thus,
evident the importance of assessing the performance of
different methods that can be applied to the analysis of
microbiome in sputum samples with a special focus on the
use of DTTand lysostaphin.
The objective of this pilot study was to compare different
conditions, such as the use of DTT as a homogenizing
agent, lytic enzymes in order to specifically target
Gram-positives and DNA extraction technique in order to
isolate bacterial DNA from sputum in adult patients with
bronchiectasis, according to different endpoints from total
DNA extraction to microbiome analysis.
Methods
Five sputum samples were collected from five adult
bronchiectasis patients followed at the Bronchiectasis
Program of the Fondazione IRCCS Ca′ Granda Ospedale
Maggiore Policlinico, Milan, Italy, in January 2018. Sub-
jects signed an informed consent and gave their approval
for using samples for the purpose of this study. Aliquots
of at least 5 ml of sputum were collected and stored at
− 80 °C for all subsequent analyses.
DNA extraction
A total of eighteen different conditions were evaluated.
Three different commercial kits for DNA extraction
were considered: 1) Roche High Pure PCR Template
Preparation Kit (Hoffmann – La Roche. Basilea.
Switzerland); 2) Zymo Quick-DNA Universal Kit (Zymo.
Irvine. CA. USA); and 3) Mobio PowerLyzer PowerSoil
DNA isolation kit (Mobio. Loker Ave West. Carlsbad.
CA. USA). Roche and Zymo use the combination of
chemical and enzyme-based lysis, while Mobio a
mechanical destruction with bead beating. Commercial
kits were used according to manufacturer’s instructions.
0.1 g from each sample was extracted with the three kits
in duplicate and eluted in 50ul elution buffer.
Two types of pre-treatments of the sputum samples,
preceding the DNA extraction itself, were considered:
the addition of dithiothreitol (DTT; Sputafluid, Biolife
Italiana Srl, Italy) 10% 1:1 in volume to 0.1 g of sputum
plugs and the enzymatic digestion with a combination of
lysozyme at 3.6 mg/ml and lysostaphin, (at both 0.18 and
0.36 mg/ml) (Sigma-Aldrich. Saint Louis. Missouri,
USA). The following six combinations of pre-treatments
were performed before using each kit: a) DTT without
enzymatic step; b) DTT with 3.6 mg/ml lysozyme and
0.18 mg/ml lysostaphin; c) DTT with 3.6 mg/ml
lysozyme and 0.36 mg/ml lysostaphin; d) without DTT
and enzymatic step; e) without DTT with 3.6 mg/ml
lysozyme and 0.18 mg/ml lysostaphin; f ) without DTT
with 3.6 mg/ml lysozyme and 0.36 mg/ml lysostaphin.
Samples were incubated at 37° for 30 min before DNA
extraction [10].
DNA extraction yield for each of the eighteen condi-
tions was measured through quantification by Quant-IT
dsDNA Assay Kit. High Sensitivity and Qubit 3.0
Fluorometer (Invitrogen, Carlsbad, CA, USA). Subse-
quently, samples were diluted at 5 ng/μl and tested in
Real Time PCR using syber green for 16S rRNA gene
amplification [12]. Each sample was tested in duplicate
and cycle threshold (Ct) mean and the standard devi-
ation was considered. Real-Time PCR for S. aureus was
conducted on DNA extracts to ensure that the addition
of lysostaphin is a useful strategy to better lyse and
recover the genomic DNA from Staphylococci [13].
Microbiome evaluation
The V3-V4 variable regions of the 16S rRNA gene were
amplified from DNA extracts using the 16S metage-
nomic sequencing library preparation protocol (Illumina,
San Diego, CA, USA). PCR products, approximately
sized 460 base pairs, were visualized using
microfluidics-based gel electrophoresis on Bioanalyzer
2100 (Agilent Santa Clara, CA, USA) and then were
cleaned using AMPure XP magnetic bead-based purifi-
cation (Beckman Coulter, Brea. CA, USA). Sample
libraries were quantified using the Qubit as reported
above and then pooled in an equimolar mode. Finally,
pool was sequenced on the MiSeq (Illumina, San Diego,
CA, USA) sequencing platform, using a 2 × 300 cycleV3
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kit and following standard Illumina sequencing
protocols.
Bioinformatic analysis
Demultiplexed paired-end reads in FASTQ format were
received from the Illumina MiSeq instrument. Sequen-
cing data were processed following the UPARSE pipeline
by Robert C. Edgar [14], using USEARCH v10.0.240 [15]
and VSEARCH v2.3.4 [16]. Overall run quality was
checked using FastQC v0.11.2 [17] and reports were
summarized using MultiQC v1.4 [18]. Quality scores
dropped towards the end of the reverse reads, so they
were globally trimmed at position 200 before merging
with the corresponding forward reads. Parameters for
paired-end reads merging were set as follows: minimum
overlapping length 19 base pairs; minimum 90% identity
of alignment; merged sequences length restricted to
430–480 bases. Consensus sequences from all samples
were pooled together and primers were stripped from
both ends. This “raw” set of merged sequences was then
quality-filtered and de-replicated to obtain a subset of
high-quality unique sequences to be clustered into Oper-
ational Taxonomic Units (OTUs). Sequences with more
than 1 expected number of errors (EE) were discarded
and singletons removed during de-replication. OTUs
were clustered at 97% identity threshold. Taxonomy pre-
diction to the genus level for OTU sequences was per-
formed via the SINTAX algorithm [19], using the RDP
training set v16 as reference database and 0.8 as confi-
dence threshold. An OTU table was constructed by
mapping the whole set of “raw” merged paired-end reads
to the representative set of OTUs, using 97% identity
threshold. It was then filtered - low abundance OTUs (<
0.5 overall frequency) discarded - and normalized to the
same number of reads per sample. This OTU table was
used for all downstream analyses. Alpha diversity was
measured for each sample using different metrics (Shan-
non entropy and Simpson estimators). These indices
were then converted to effective number of species
(ENOS) [20] to be easily compared to each other.
Study endpoints and statistical analysis
The following results have been compared across the 18
different conditions: Extracted DNA yield, Real-time
PCR for 16 s rRNA gene, Diversity indices, including
Shannon entropy and Simpson estimators and their con-
version into ENOS. Relative abundances and Real-time
PCR for S. aureus. Relative abundances have been com-
pared with results of standard microbiology.
One-way ANOVA with post hoc Bonferroni test has
been conducted on Real-Time PCR data with a signifi-
cance level of 0.05. Statistical analysis was performed in
the R environment.
Results
DNA was recovered from all the five sputum samples. A
higher quantity of DNA has been extracted using Roche
and Zymo kits in comparison to Mobio one; the median
values of extracted DNA across the 6 different condi-
tions for Roche, Zymo and Mobio kits were 26.062,
19.750 and 1.233 μg respectively. Detailed median (IQR)
values of extracted DNA for all the 18 different condi-
tions are reported in Fig. 1.
Results of the real-time PCR for 16S rRNA gene for
each condition (Fig. 2), show that no significant differ-
ences across the 18 conditions (range of medians be-
tween 20 and 21 Ct).
Real-time PCR for S. aureus has been performed for
all samples and was positive for two of them. The
addition of the enzymatic digestion step increased
Staphylococcus DNA extraction (Fig. 3). A similar pat-
tern can be observed through all the conditions even if
no statistical evidence is present.
In terms of alpha diversity, no significant differences
have been detected among the 18 evaluated conditions,
neither considering the Shannon index (range of median
values: 0.492–0.574), nor the Simpson (range of median
values: 0.624–0.692). Evaluation made using ENOS from
Shannon index (range of median values: 1.6–1.8) and
ENOS from Simpson index (range of median values:
2.7–3.3), did not show any appreciable difference
(Fig. 4).
Relative abundances at the genus level of identified
bacteria in each sputum sample across the 18 evaluated
conditions are reported in Fig. 5. Microbiome compos-
ition is very different across different samples. Sputum
samples presenting few genera have very similar data,
while in the presence of a higher number of bacterial
genera (Patient 2 and 4) differences emerge when com-
paring the same condition with and without DTT. In
sputum sample 5, where only two genera are present,
there is an increase of Staphylococci presence in samples
treated with lysostaphin and lysozyme. Relative abun-
dances of the four most abundant bacteria detected in
each sputum sample across the 18 evaluated conditions
are reported in (Additional file 1: Table A).
Discussion
The major finding of the present experience is that the
18 different conditions evaluated seem to equally per-
form in extracting DNA from sputum samples in terms
of Real-Time PCR for 16 s rRNA gene, alpha diversity
and relative abundances of bacterial genera. However,
the DNA extraction yield seems to be higher if Roche
and Zymo kits are used in comparison to the Mobio
one.
The use of enzymatic techniques seems to allow a
higher DNA extraction yield than mechanical ones. A
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high yield might be preferred for 16 s rRNA sequencing
because sputum is a matrix with a high percentage of
human DNA. For this reason, in order to prepare
libraries with an acceptable bacterial DNA amount and
more representative for the microbiota of the sample,
the starting amount of DNA loaded into PCR need to be
high. In order to overcome this limitation, it is possible
to either increase the amount of sputum collected by
patients or, in case of a limited amount of sputum
sample, select a technique able to obtain a high yield of
DNA (such as Roche or Zymo kits).
Both the evaluated pre-treatments seem to play a cru-
cial role. The addition of lytic enzymes is important to
enhance S. aureus DNA extraction; however, an increase
of lysostaphin concentration over 0.18 mg/mL seems not
to increase the performance of the kit to extract DNA.
Fig. 1 Comparison between median (IQR) levels of DNA extraction yield across 18 evaluated conditions
Fig. 2 Comparison between median (IQR) levels of 16 s rRNA gene Real-Time PCR across 18 evaluated conditions
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Fig. 3 Comparison between median levels (IQR) of Real-Time PCR for S. aureus in sputum samples and across the 18 evaluated conditions
Fig. 4 Comparison of median levels of Alpha diversity across the 18 evaluated conditions expressed as Shannon index and relative effective
number of species (ENOS) (a and b), and Simpson index and relative ENOS (c and d)
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These results, first identified through Real-Time PCR for
S. aureus, are confirmed by an increase in Staphylococcus
genus identification through sequencing. The addition of
DTT has a role in improving data reproducibility.
Through sequencing, we saw that the presence of DTT
seemed to be able to better homogenize sputum samples,
leading to more reproducible results in terms of bacterial
genera detected, and at the same time seems not to affect
the efficiency of DNA extraction. Relative abundances in
sputa presenting a large number of bacterial genera are
very similar in conditions with DTT, while they vary
greatly but very different when it is absent. In sputum
sample 2 there are differences in extraction of Stenotro-
phomonas genus, greatly improved in absence of DTT,
presence of 0.18mg/ml lysostaphin and treated with
Zymo kit. Comparing this result with the same condition,
in presence of DTT we might speculate that the difference
is given by sampling. DTT enable the release of bacteria
entrapped into sputum matrix. For this reason, the repeti-
tion of the analysis on the same sample leads to compar-
able results. If a homogenization step is not present,
differences given by sampling can be present.
This study has some limitations. First, different inter-
ventions, such as the use of DTT and lysostaphin, have
been performed at the same time, while no sequential
approach has been used. Although this might help us in
evaluating possible synergies between variables, difficul-
ties in data interpretation might be present without a
special focus on a single variable. Second, the mono-
centric design, the low number of samples collected and
the fact that no patients other than bronchiectasis have
been enrolled might interfere with the generalizability of
our results. Third, only three kits have been considered,
although others are on the market. Finally, our study did
not take into account the possible presence of initial
contamination of commercial kits.
This is the first pilot study that tried to address
relevant methodological questions in microbiome
analysis of sputum samples and took into consideration
not only a comparison among different commercial kits
but also different pre-treatments of sputum samples.
Furthermore, the performance of 18 different conditions
for DNA extraction from sputum has been evaluated
considering different endpoints. Real-time PCR for both
16 s rRNA gene allowed us to understand if all methods
were able to extract bacterial DNA with the same effi-
ciency; Real-time PCR for S. aureus has been performed
in order to evaluate lytic enzymes activity; Microbiome
analysis considering alpha diversity indices and relative
abundances.
Fig. 5 Relative abundances of bacterial genera in each of the 5 sputum samples across the 18 evaluated conditions
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Conclusions
The use of a unique method for DNA extraction and
microbiome analysis of sputum samples is very import-
ant in translational research and could represent a step
forward in the introduction of microbiome analysis in
clinical practice. A homogeneity of methods for micro-
biome analysis is needed as well as data coming from
different centers which are needed to improve the repro-
ducibility of the method. These data should be import-
ant for the development of new methods in order to
have an improvement of DNA extraction techniques for
microbiome analysis.
None of the 18 evaluated conditions seems to be su-
perior to the other ones in extracting DNA from sputum
samples, although a higher amount of extracted DNA
could be obtained using enzyme-based commercial kits.
Pre-treatments with lysostaphin, lysozyme and DTT
seem to be necessary in order to have the most
representative microbiome evaluation possible. Further
studies will be necessary in order to confirm our data.
Moreover, these preliminary data show that neither syn-
ergic nor interfering effect is present between variables.
Punctual evaluation of variables in an independent way
should be needed in order to better address this issue.
The hypothesis of evaluating microbiome from the same
sputum samples in accordance with the same standard
operating procedures across different international cen-
ters will be considered in case of multicenter studies on
microbiome analysis will be designed in the next future.
Additional file
Additional file 1: Table A. Relative abundances of the four most
abundant bacteria detected in each sputum sample across the 18
evaluated conditions (in percentage). (DOCX 27 kb)
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